Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 ...

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

Unfortunately, not even the implementation of the Generics Act of 1988, also known as Republic Act No. 6675, or a law that aims to produce affordable but effective medicines available to the public, ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...